The latest announcement is out from IO Biotech (IOBT).
On August 30, 2024, the Company revealed positive news from its Phase 3 trial of the cancer vaccine IO102-IO103 used with KEYTRUDA® for treating advanced melanoma, with an Independent Data Monitoring Committee endorsing the trial’s continuation. This endorsement, based on favorable safety and efficacy data, signals steady progress towards the primary endpoint expected in early 2025, generating optimism among investors and stakeholders in the pharmaceutical sector.
For an in-depth examination of IOBT stock, go to TipRanks’ Stock Analysis page.
